Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Engage in a focused presentation on how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.
This session aims to explore the critical contributions of Nu.Q® Technology to clinical epigenetics research, emphasizing its role in the identification and validation of biomarkers for epigenetic drug discovery. We will discuss the technology’s capability in monitoring treatment responses and its utility in elucidating the underlying mechanisms of disease processes.
Key Topics Include:
- Next-Generation Epigenetic Immunoassay for Quantitative Assessment of Circulating Nucleosomes
- Nu.Q Technology for determining levels of circulating nucleosomes
- Pre-clinical through Clinical Development of Circulating Nucleosomes as Pharmacodynamic Biomarkers in Oncology Trials
- Histone PTMs at biomarkers for therapeutics targeting chromatin regulators
- Liquid biopsy to monitor target engagement of inhibitors of PRC2 subunits including histone methyl transferase EZH2 and its allosteric regulator EED
- Precision oncology strategy for selecting patients with H3K27me3 accumulation
- PD-1/PD-L1 checkpoint inhibitor combination with EZH2i/EEDi
- Expanding Utility of Circulating Nucleosomes to Monitor/Predict Adverse Reactions to CAR-T cell therapy
- Neutrophil release of inflammatory mediators and decondensed DNA (NETosis) before and during the onset of cytokine release syndrome (CRS)
- Monitoring NETosis with Nu.Q
By the end of this discussion, attendees will:
- Gain a nuanced understanding of the emerging opportunities in biomarker-driven, epigenetic therapeutic development.
- Acquire insights into the future potential of nucleosome markers as versatile tools for cancer response and toxicity monitoring.
- Categories: Cancer & Oncology Research, Drug Discovery & Development, Genetics & Genomics
- Tags: biomarkers, cancer biomarkers, cancer immunotherapy, cancer treatment, clinical trials, drug efficacy, drug toxicity, ELISA, epigenetic
Presenters
Eric A. Ariazi, PhD
Consultant
Volition
Eric A. Ariazi, PhD, is a distinguished Translational Medicine Scientist with 25+ years of experience spanning academia and industry.
Terry Kelly, PhD
Chief Innovation Officer/Chief Scientific Officer
VolitionRx/Volition America
Dr. Terry Kelly is the Chief Innovation Officer for VolitionRx and Chief Scientific Officer for Volition America.
Production Partner
Volition
Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling nucleosomes.
Additional Content From Scientist.com
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Preclinical Animal Models of IBD, GVHD, and Pulmonary Disease
Join BioModels’ Scientists, Andrew Borkowski, PhD and Nicole Smith, PhD, as they discuss a selection of key preclinical models of inflammatory disease, including models of Inflammatory Bowel Disease (IBD)/colitis, Graft vs Host Disease (GvHD), and pulmonary disease, focusing on the utility of clinically relevant endpoints that create highly translational models of human disease.
Related Content
Applications of Human Intestinal Organoid Cultures in Drug Discovery
Join STEMCELL TEchnologies' experts as they discuss the use of human intestinal organoid cultures in drug discovery and toxicity testing.
Next-Generation Safety Assessment Tools for Advancing In Vivo to In Vitro Translation
In this webinar, Dr. Louis Scott discusses the morph_ONE™ assay, a novel tool for in vitro safety assessment in drug development.
Organoid Meets Microelectrode Array (MEA) – Accelerating Drug Discovery and Development
In this webinar, Dr. Sven Schönecker and Sara Mirsadeghi, MSc, will discuss 3D Mesh Microelectrode Arrays (MEA) including new developments and applications.
